Editas Medicine, Inc. Stock News

Gene editing seems like a great idea: Instead of masking the symptoms of disease, we actually change the genes to bring permanent change that actually removes the disease. The platform used nowadays to do this is known as Crispr. I previously covered two companies, Crispr Therapeutics and Intellia Therapeutics, that license and use this intellectual property. Editas Medicine is also a Crispr li...

Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models

CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 7-10, 2025, in Seville, Spain.

Editas Medicine, Inc. - Special Call Company Participants Gilmore O'Neill - President, CEO & Director Linda Burkly - Executive VP & Chief Scientific Officer Conference Call Participants Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Samantha Semenkow - Citigroup Inc., Research Division Alec Stranahan - BofA Securities, Research Division Mehdi Goudarzi - Truist Securities, In...

EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into second quarter of 2027 Company-sponsored webinar on EDIT-401 today at 8:00 a.m. ET CAMBRIDGE, Mass.

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce the selection of its lead in vivo development candidate.

CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September: Wells Fargo Healthcare Conference Format: One-on-one MeetingsDate: Wednesday, September 3Locat...

Gene-editing company Editas Medicine (EDIT -4.06%) was something of an unexpected star on the stock exchange as the trading week came to a close. The small biotech's share price was up by a robust 34% week to date as of early Friday morning, according to data compiled by S&P Global Market Intelligence, thanks to a well-received quarterly earnings report and business update.